Title
Category
Credits
Event date
Cost
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo.
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc.
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored.
  • Oncology
  • AMA PRA Category 1 Credit™
$0.00
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca.
  • Psychiatry
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
​​​​​​Join Drs Les Citrome, Steve Stoner, and Board Certified Family Psychiatric Nurse Practitioner Tory Woodward for this on-demand online activity, as they discuss considerations for implementing LAI clinics and best practices for communicating with patients, caregivers, and clinicians regarding the use of LAIs during the global health pandemic of COVID-19.  This activity is supported by an educational grant from Alkermes.
  • Psychiatry
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
In recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality. Also, much evidence suggests the use of these treatments should no longer be reserved for last line, but offered at an earlier place in the illness. Moreover, new agents have arrived on the market which can be dosed without oral overlap, paving the way to less burdensome initiation strategies. Join Drs.